| Brent Alexander Knight, | |
|
820 N Chelan Ave, Wenatchee, WA 98801-2028 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Brent Alexander Knight |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 5 Years |
| Location | 820 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457713240 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD61144888 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Washington Hospital | Wenatchee, WA | Hospital |
| Mid Valley Hospital | Omak, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Washington Health Services Association | 4880504596 | 645 |
News Archive
New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
A broad retrospective review of the effects of coronary artery bypass grafting (CABG) on memory and other brain functions concludes that, while there may be transient short-term effects, the procedure itself probably does not cause late or permanent neurological effects.
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
› Verified 4 days ago
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
A broad retrospective review of the effects of coronary artery bypass grafting (CABG) on memory and other brain functions concludes that, while there may be transient short-term effects, the procedure itself probably does not cause late or permanent neurological effects.
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
› Verified 4 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
A broad retrospective review of the effects of coronary artery bypass grafting (CABG) on memory and other brain functions concludes that, while there may be transient short-term effects, the procedure itself probably does not cause late or permanent neurological effects.
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brent Alexander Knight, 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Brent Alexander Knight, 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 |
News Archive
New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).
A broad retrospective review of the effects of coronary artery bypass grafting (CABG) on memory and other brain functions concludes that, while there may be transient short-term effects, the procedure itself probably does not cause late or permanent neurological effects.
Cancer cells may be able to avoid destruction by anti-vascular and anti-angiogenesis agents through a cellular stress response that activates a pro-survival protein called GRP78, according to researchers from the Keck School of Medicine of the University of Southern California.
Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.
› Verified 4 days ago
Travis M Clark, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Cheryl S Shih, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Ian Mclaren, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dale T Peterson, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
James Mansel Harris, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Jeffrey M Monda, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |